Table 2.
Demographic variables, motor function, non-motor symptoms, and ADL of PD-D and PD-ND groups.
| PD-ND group (196 cases) | PD-D group (282 cases) | P | |
|---|---|---|---|
| DEMOGRAPHIC INFORMATION | |||
| Female (n, %) | 87 (44.39%) | 150 (53.19%) | 0.058 |
| Age (year, ) | 63.00 (56.00–70.00) | 61.50 (55.75–69.00) | 0.278 |
| Age of onset (year, ) | 59.87 ± 11.16 | 57.51 ± 10.89 | 0.024* |
| Disease duration [year, Median (Q1-Q3)] | 2.00 (1.00–4.00) | 3.00 (1.00–5.00) | <0.001** |
| Low education level (<9 years) (n, %) | 93 (47.45%) | 176 (62.41%) | <0.001** |
| Left side of onset (n, %) | 82 (41.84%) | 132 (46.81%) | 0.282 |
| ANTI-PARKINSON DRUG | |||
| LEDD [mg, M (Q1-Q3)] | 0.75 (0, 6.90) | 1.16 (0, 3.00) | 0.341 |
| Kinds of Anti-parkinson drug | |||
| Madopar (n, %) | 85 (43.37%) | 144 (51.06%) | 0.098 |
| Sinemet CR (n, %) | 12 (6.12%) | 20 (7.09%) | 0.677 |
| Entacapone (n, %) | 7 (3.57%) | 19 (6.74%) | 0.133 |
| Pramipexole (n, %) | 45 (22.96%) | 48 (17.02%) | 0.107 |
| Piribedil CR (n, %) | 36 (18.37%) | 49 (17.38%) | 0.780 |
| Selegiline (n, %) | 4 (2.04%) | 4 (1.42%) | 0.722 |
| Antane (n, %) | 9 (4.59%) | 23 (8.16%) | 0.125 |
| Duration of anti-PD therapy | |||
| ≤ 1 year | 61 (31.12%) | 82 (29.08%) | 0.059 |
| >1– ≤ 3years | 84 (42.86%) | 96 (34.04%) | |
| >3– ≤ 7years | 35 (17.86%) | 64 (22.70%) | |
| >7years | 16 (8.16%) | 40 (14.18%) | |
| MOTOR FUNCTION | |||
| H-Y stage (n, %) | |||
| Early stage (stage 1–2.5) | 179 (91.33%) | 224 (79.43%) | <0.001** |
| Advanced score (stage 3–5) | 17 (8.67%) | 58 (20.57%) | |
| Total UPDRS III [point, Median (Q1-Q3)] | 18.00 (12.00–27.00) | 28.00 (19.00–40.00) | <0.001** |
| Tremor | 3.00 (2.00–6.00) | 5.00 (2.00–8.00) | |
| Rigidity | 3.00 (1.00–5.00) | 5.00 (2.00–9.00) | |
| Bradykinesia | 7.00 (5.00–11.00) | 11.00 (7.00–16.00) | |
| Postural instability/gait difficulty | 3.00 (2.00–4.00) | 4.00 (3.00–6.00) | |
| CLINICAL TYPE (n, %) | |||
| TD subtype | 67 (35.40) | 6 (2.70) | <0.001** |
| PIGD subtype | 106 (52.40) | 276 (97.30) | |
| Mixed subtype | 25 (12.20) | 0 (0.00) | |
| NON-MOTOR SYMPTOMS | |||
| MoCA [point, Median (Q1-Q3)] | 23.00 (19.00–27.00) | 21.00 (16.00–25.00) | <0.001** |
| HAMA [point, Median (Q1-Q3)] | 3.00 (1.00–5.00) | 12.00 (8.00–17.75) | <0.001** |
| FS [point, Median (Q1-Q3)] | 7.00 (4.00–10.00) | 10.00 (8.00–12.00) | <0.001** |
| RBDSQ [points, Median (Q1-Q3)] | 1.00 (0.00–4.00) | 3.00 (1.00–7.00) | <0.001** |
| SCOPA-AUT [points, Median (Q1-Q3)] | 33.00 (29.00–37.00) | 36.00 (32.00–43.00) | <0.001** |
| RLSRS [point, Median (Q1-Q3)] | 0.00 (0.00–6.00) | 0.00 (0.00–18.00) | <0.001** |
| ADL | |||
| ADL [point, Median (Q1-Q3)] | 22.00 (20.00–30.00) | 32.50 (23.00–42.25) | <0.001** |
*
P < 0.05;
**
P < 0.01. LEDD, levodopa equivalent daily dose; Sinemet CR, controlled release Sinemet; Piribedil C, controlled release Piribedil; UPDRS III, Unified Parkinson's Disease Rating Scale III; TD, tremor-dominant; PIGD, postural instability/gait difficulty; MoCA, Montreal Cognitive Assessment Scale; HAMA, the 14-item Hamilton Anxiety Scale; FS, the 14-item Chalder Fatigue Scale; RBDSQ, the Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire; SCOPA-AUT, the Scale for Outcomes in PD for Autonomic Symptoms; RLSRS, Restless Legs Syndrome Severity Rating Scale.